Sean Bedingfield
@seanbedingfield
Drug Delivery Specialist - Lilly Institute of Genetic Medicine (Opinions are my own)
ID: 1482955267
04-06-2013 18:26:43
458 Tweet
380 Followers
520 Following
Researchers synthesized a new class of temperature-responsive, dual-crosslinking, biohybrid injectable hydrogels with enhanced vascularization properties for broad applications. buff.ly/2YXDhuA Joanna Palade Arizona State University ASU Ira A. Fulton Schools of Engineering #SciTwitter #SciComm #AcademicChatter
Looking forward to today's Integrating Women Leaders conference, home of positive dialogue for change AND the finger-sized foam finger IWL Foundation #iwlbethechange
Hey Martina Di Francesco(Martina Di Francesco), thank you for following me
Hey Valentina Di Francesco(Valentina Di Francesco), thank you for following me
John Clegg Duvall Lab Harvard SEAS Come check out some interesting work by my awesome mentor Sean Bedingfield and labmate William Tierney Duvall Lab 😎🧬💊
It takes a village Duvall Lab. Thanks to all of you for teaching me and being the proxy grad school family we need for this type of work!
A special thanks to ACS Nano for a speedy review, Martina Di Francesco & Paolo G. Decuzzi for helping bring this idea to life, and Juan Manuel Colazo and Duvall Lab for bringing this effort across the finish line!
#ResearchHighlight | Targeting articular Mmp13 in OA #osteoarthritis #nanotechnology Read the original research from Duvall Lab Sean Bedingfield Juan Manuel Colazo Vanderbilt BME Vanderbilt Rheumatology Nature Biomedical Engineering here go.nature.com/3tCUHKc Read our #news story here go.nature.com/3EqBIb0
A Vanderbilt BME team has demonstrated the potential for the first osteoarthritis drug that interrupts the process of post-traumatic osteoarthritis. The Duvall Lab has developed short interfering RNA-based drugs known as siRNAs. ow.ly/9vhq50GazsR